文献速递头颈外科

复发性口咽癌患者与照护者关于诊断、治疗及带瘤生活的体验

Patient and Caregiver Experience of Diagnosis, Treatment, and Living With Recurrent Oropharyngeal Cancer.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2025-01-01

该研究在英国一家专科癌症中心对22例经活检确诊的复发性口咽癌患者及7名照护者进行纵向前瞻性与回顾性定性研究,通过半结构化深度访谈和框架法主题分析,探讨其诊断、治疗及功能与生活质量变化的体验。研究发现,患者和照护者常将复发体验置于原发疾病诊疗经历中理解;当治愈与功能受损的生活质量二选一时,患者倾向选择治愈,而无治愈选项时则希望尽可能延长生存;随着预后缩短,功能与生活质量优先于生存。治疗决策常基于医疗专业人员对挽救性手术「功能损害过大」或非治愈治疗「更温和」的认知,但患者并不总是充分参与,共享决策并非总能实现。

要点

  • 患者和照护者将复发性口咽癌的体验置于原发疾病诊断与治疗的既往经历中理解。
  • 当治愈与功能/生活质量二选一时,患者倾向选择治愈;无治愈选项时希望尽可能延长生存。
  • 随着预后缩短,功能与生活质量优先于生存;患者并非总充分参与决策,共享决策并非总能实现。

核心结论

  • 复发性口咽癌的治疗决策极其复杂,常基于医疗专业人员对挽救性手术功能损害过大或非治愈治疗更温和的认知,但患者并不总是充分参与,共享决策并非总能实现。
  • 为促进共享决策和知情同意,需向患者提供复发性口咽癌各种治疗方式在生存和功能/生活质量结局方面的清晰准确信息。

研究设计与样本

  • 在英国一家专科癌症中心开展的纵向前瞻性与回顾性定性研究,纳入经活检确诊的复发性口咽癌患者及其照护者。
  • 参与者于2022年12月至2023年11月招募,同时期数据分析于2023年11月至2024年1月进行。
  • 暴露因素为治愈性挽救性手术或非治愈性免疫治疗、化疗或研究性药物的临床试验。
  • 主要结局为对半结构化深度访谈进行框架法主题分析。
  • 共招募22例患者和7名照护者;纵向样本包括8名男性和2名女性,中位年龄62岁(范围47-77岁);回顾性样本包括11名男性和1名女性,中位年龄64岁(范围59-70岁);11例(50%)接受治愈性治疗,11例(50%)接受非治愈性治疗。

主要发现

  • 患者和照护者将复发性疾病的体验置于原发疾病诊断与治疗的既往经历中理解。
  • 患者希望生存;当可选方案为治愈或影响健康相关生活质量的功能结局时,治愈似乎更受青睐。
  • 当治愈不是选项时,患者似乎希望尽可能延长生存;但随着预后缩短,优先级似乎发生转变,功能/生活质量优先于生存。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The management of recurrent oropharyngeal cancer (rOPC) is complex. Curative options carry considerable risk of morbidity with overall poor prognosis. Little data exist on function and quality of life (QoL) outcomes for noncurative treatments. Even less is known about patient and carer experiences of function and QoL change over time when undergoing curative or noncurative treatment(s) for rOPC. OBJECTIVE: To investigate the patient and caregiver experience of diagnosis, treatment, and living with recurrent oropharyngeal cancer and changes to function/QoL. DESIGN, SETTING, AND PARTICIPANTS: A longitudinal prospective and retrospective qualitative study was carried out at a specialist cancer center in the United Kingdom. Participants with a biopsy proven diagnosis of recurrent OPC and their caregivers were included. Participants were recruited between December 2022 and November 2023. Concurrent data analysis took took place between November 2023 and January 2024. EXPOSURE: Curative salvage surgery or noncurative immunotherapy, chemotherapy, or clinical trials of investigational agents. MAIN OUTCOMES: A framework-approach thematic analysis of semistructured, in-depth interviews. RESULTS: Twenty-two patients and 7 caregivers were recruited. Demographic data was collected via medical record review. The longitudinal sample included 8 male and 2 female individuals, and the median age was 62 (range, 47-77) years. The retrospective sample included 11 male individuals and 1 female individual, and the median age was 64 (range, 59-70) years. Eleven participants (50%) underwent curative treatment, and 11 (50%) noncurative treatment.Treatments included salvage surgery, immunotherapy, chemotherapy, or clinical trials. Patients and their caregivers contextualize their experience of recurrent disease in their past experience of primary disease diagnosis and treatment. Patients want to survive and when the options to choose between are cure or functional outcomes impacting health-related QoL, cure appears to be favored. However, when cure is not an option, patients appear to want to survive as long as possible. However, as the prognosis gets shorter there appears to be a shift in priorities where function/QoL take precedence over survival. CONCLUSIONS AND RELEVANCE: This qualitative study found that treatment decision-making is extremely complex in the setting of rOPC. Quite often, decisions are made based on what is perceived by health care professionals to be functionally "too morbid" with salvage surgery, or "kinder" with life-prolonging noncurative treatments. However, patients are not always fully involved in these decisions and so shared decision-making does not always happen. To facilitate shared decision-making and informed consent, patients need to be given clear and accurate information on survival and function/QoL outcomes for the various treatment modalities for rOPC.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Brady G, Roe J, Paleri V, et al. Patient and Caregiver Experience of Diagnosis, Treatment, and Living With Recurrent Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 39570619. doi:10.1001/jamaoto.2024.3757

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。